Article

Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors

2022-04-05

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Immune checkpoint inhibitors (ICIs) are a valuable treatment option for patients with malignant tumors, but only selected patients respond to ICIs. Available biomarkers are of limited use in guiding ICI therapy. <h4>Objective</h4> To examine clinicians’ perspective on the use of ICIs and biomarkers for treatment of malignant tumors and to identify unmet needs related to their...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c0028e0d-04bd-51f9-b4e4-00aca542a07d
DOI: 10.1101/2022.04.01.22269254

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumorsDOI 10.1101/2022.04.01.22269254Read

Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint InhibitorsSemantic proximity Read

Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology TrialsSemantic proximity Read

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.Semantic proximity Read

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read

Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical SettingSemantic proximity Read

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Semantic proximity Read

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumoursSemantic proximity Read

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major CancersSemantic proximity Read

Real‐world data on microsatellite instability status in various unresectable or metastatic solid tumorsSemantic proximity Read

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read

Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysisSemantic proximity Read